NEW YORK – The University of Minnesota on Monday announced that it had begun enrolling patients in a Phase II clinical trial evaluating a personalized, CRISPR-edited, T-cell therapy for patients with metastatic gastrointestinal solid tumors.
NEW YORK – The University of Minnesota on Monday announced that it had begun enrolling patients in a Phase II clinical trial evaluating a personalized, CRISPR-edited, T-cell therapy for patients with metastatic gastrointestinal solid tumors.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.